MediPharm Labs has signed a deal with Malta-based MT Pharma to supply GMP-certified, finished-dose cannabis oil for patients.
Under the terms of the two-year agreement, signed through MediPharm’s Australian subsidiary, the company will provide pre-formulated, GMP-certified, full-spectrum cannabis concentrates that will be distributed to patients through pharmacies that will complete final formulation and fill.
MediPharm Labs president and interim CEO Keith Strachan said: “The global cannabis marketplace continues to grow at a rapid pace which is prompting established pharmaceutical, wellness and brand companies to enter the industry.
“Many have chosen to develop products, secure a GMP-certified supply chain and open distribution channels through a partnership with MediPharm.”
“We are proud to be the provider of choice for pharmaceutical and wellness companies in nine countries and counting. These customers have contracted MediPharm to provide a turnkey solution to enhance their offerings with innovative, high-quality wellness products, and future potential registered pharmaceutical drugs containing cannabis, to meet patient and physician demand for personalised therapeutics and medicines.”
In the last three months, MediPharm has completed export of cannabis-based derivative products to multiple customers in Germany, Peru and Australia, and has expanded its product offerings and distribution footprint in Canada.
The company expects to begin exports to other countries this year including Brazil, Malta, Denmark and New Zealand.